FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2008210460> ?p ?o ?g. }

• W2008210460 abstract "Recent clinical data suggests that the anti EGFR antibodies, cetuximab and panitumumab, are ineffective in patients with colorectal cancer whose tumors harbor a mutation in the kras oncogene. Currently, for these patients, the only option after failure of front line therapy is irinotecan, and there is no drug that can be combined with it to improve clinical outcomes. We studied in vitro, the combination of Reolysin and irinotecan to develop a novel therapeutic approach for these patients. Reolysin (reovirus Serotype 3) has been shown to replicate specifically in tumors bearing an activated ras pathway. This specificity coupled with its relatively nonpathogenic nature in humans makes it an attractive anti-cancer therapy candidate. We have performed in vitro studies of Reo (multiplicity of infection 1 to 10), iri (0.5-10 µM), as single agents and in combination in human colorectal cancer cells to study the role of kras mutation. Reolysin was obtained from Oncolytics Biotech Inc. and irinotecan was obtained commercially. A panel of 8 colorectal cancer cell lines were infected with Reolysin (multiplicity of infection 1 to 10), irinotecan (0.5-10 µM), as a single agent or in combination. The cells were exposed to Reolysin for 6-8 hours and to irinotecan for 72 hours. Viable cells were determined 72 hours post treatment using MTT assay. The effect of Reolysin and irinotecan combination on cell viability was assessed using CalcuSyn software (Biosoft, UK) that generates combined cytotoxic effect by calculating combination indices (CIs). A CI of 1 denotes antagonism. We found that Reolysin and irinotecan as single agents were cytotoxic to all colon cell lines studied. Further, when Reolysin was combined with irinotecan, there was evidence of synergistic cytotoxicity in all (HT29, HCT116, DLD, KM12, SKCO-1, SW620, LIM2405) except one (SW948) cell line. There appears to be no association between kras mutation status and synergism. To further explore these findings and understand the mechanistic basis of drug synergism we are studying the effect of Reolysin and irinotecan in isogenic HCT116 (kras mutant) and Hke3 (kras WT) cell lines. In summary, the combination of Reolysin and irinotecan is synergistic in colorectal cancer cell lines including those with kras mutation and is worthy of exploration in human patients. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1773." @default.
• W2008210460 created "2016-06-24" @default.
• W2008210460 creator A5006031207 @default.
• W2008210460 creator A5029455802 @default.
• W2008210460 creator A5038419173 @default.
• W2008210460 creator A5050975158 @default.
• W2008210460 creator A5070227595 @default.
• W2008210460 date "2010-04-15" @default.
• W2008210460 modified "2023-09-25" @default.
• W2008210460 title "Abstract 1773: The addition of Reolysin, an oncolytic reovirus, to irinotecan shows synergistic anticancer activity in colorectal cancer cell lines" @default.
• W2008210460 doi "https://doi.org/10.1158/1538-7445.am10-1773" @default.
• W2008210460 hasPublicationYear "2010" @default.
• W2008210460 type Work @default.
• W2008210460 sameAs 2008210460 @default.
• W2008210460 citedByCount "1" @default.
• W2008210460 countsByYear W20082104602020 @default.
• W2008210460 crossrefType "proceedings-article" @default.
• W2008210460 hasAuthorship W2008210460A5006031207 @default.
• W2008210460 hasAuthorship W2008210460A5029455802 @default.
• W2008210460 hasAuthorship W2008210460A5038419173 @default.
• W2008210460 hasAuthorship W2008210460A5050975158 @default.
• W2008210460 hasAuthorship W2008210460A5070227595 @default.
• W2008210460 hasConcept C121608353 @default.
• W2008210460 hasConcept C126322002 @default.
• W2008210460 hasConcept C143998085 @default.
• W2008210460 hasConcept C203014093 @default.
• W2008210460 hasConcept C203233990 @default.
• W2008210460 hasConcept C2522874641 @default.
• W2008210460 hasConcept C2776248978 @default.
• W2008210460 hasConcept C2779682216 @default.
• W2008210460 hasConcept C2779998722 @default.
• W2008210460 hasConcept C2780259306 @default.
• W2008210460 hasConcept C2781187634 @default.
• W2008210460 hasConcept C502942594 @default.
• W2008210460 hasConcept C526805850 @default.
• W2008210460 hasConcept C55493867 @default.
• W2008210460 hasConcept C71924100 @default.
• W2008210460 hasConcept C82210918 @default.
• W2008210460 hasConcept C86803240 @default.
• W2008210460 hasConcept C98274493 @default.
• W2008210460 hasConceptScore W2008210460C121608353 @default.
• W2008210460 hasConceptScore W2008210460C126322002 @default.
• W2008210460 hasConceptScore W2008210460C143998085 @default.
• W2008210460 hasConceptScore W2008210460C203014093 @default.
• W2008210460 hasConceptScore W2008210460C203233990 @default.
• W2008210460 hasConceptScore W2008210460C2522874641 @default.
• W2008210460 hasConceptScore W2008210460C2776248978 @default.
• W2008210460 hasConceptScore W2008210460C2779682216 @default.
• W2008210460 hasConceptScore W2008210460C2779998722 @default.
• W2008210460 hasConceptScore W2008210460C2780259306 @default.
• W2008210460 hasConceptScore W2008210460C2781187634 @default.
• W2008210460 hasConceptScore W2008210460C502942594 @default.
• W2008210460 hasConceptScore W2008210460C526805850 @default.
• W2008210460 hasConceptScore W2008210460C55493867 @default.
• W2008210460 hasConceptScore W2008210460C71924100 @default.
• W2008210460 hasConceptScore W2008210460C82210918 @default.
• W2008210460 hasConceptScore W2008210460C86803240 @default.
• W2008210460 hasConceptScore W2008210460C98274493 @default.
• W2008210460 hasLocation W20082104601 @default.
• W2008210460 hasOpenAccess W2008210460 @default.
• W2008210460 hasPrimaryLocation W20082104601 @default.
• W2008210460 hasRelatedWork W1849035610 @default.
• W2008210460 hasRelatedWork W2027242489 @default.
• W2008210460 hasRelatedWork W2031925505 @default.
• W2008210460 hasRelatedWork W2039710015 @default.
• W2008210460 hasRelatedWork W2047298889 @default.
• W2008210460 hasRelatedWork W2055209074 @default.
• W2008210460 hasRelatedWork W2072873806 @default.
• W2008210460 hasRelatedWork W2129772273 @default.
• W2008210460 hasRelatedWork W2165054052 @default.
• W2008210460 hasRelatedWork W2309999272 @default.
• W2008210460 hasRelatedWork W2322326083 @default.
• W2008210460 hasRelatedWork W2335300863 @default.
• W2008210460 hasRelatedWork W2803616070 @default.
• W2008210460 hasRelatedWork W2886280897 @default.
• W2008210460 hasRelatedWork W2887201603 @default.
• W2008210460 hasRelatedWork W2890323486 @default.
• W2008210460 hasRelatedWork W2953541756 @default.
• W2008210460 hasRelatedWork W2955206426 @default.
• W2008210460 hasRelatedWork W2976628266 @default.
• W2008210460 hasRelatedWork W2978030504 @default.
• W2008210460 isParatext "false" @default.
• W2008210460 isRetracted "false" @default.
• W2008210460 magId "2008210460" @default.
• W2008210460 workType "article" @default.